By Drug Target Review2026-01-15T10:10:53
Researchers have shown that changing the molecular structure of NK1 receptor antagonists may restore antidepressant effects after decades of failed trials.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2023-01-19T15:38:17
Sponsored by Cell Signaling Technology
2023-03-08T16:29:20
Sponsored by Bio-Techne
2025-04-22T14:58:00
Sponsored by Takara Bio USA
2023-05-18T10:39:07
Sponsored by BPS Bioscience
2025-05-14T14:30:00
Sponsored by Abzena
2023-03-28T11:38:32
Sponsored by Bio-Techne
Site powered by Webvision Cloud